Eli Lilly lifts 2026 revenue guidance to $87 billion after Zepbound and Mounjaro drive quarterly beat
LLY is in focus after Eli Lilly easily topped quarterly earnings estimates and raised its full-year 2026 revenue outlook, with Zepbound and Mounjaro sales cited as the demand catalyst. The company now guides for 2026…
Key takeaways
- Eli Lilly raised its full-year 2026 revenue guidance to a range of $85 billion to $87 billion, up from a prior range of $82 billion to $85 billion.
- The company topped quarterly earnings estimates, citing Zepbound and Mounjaro sales as the demand catalyst.
- Both the low end ($82B to $85B) and high end ($85B to $87B) of the 2026 revenue range were raised.
- The new ceiling for Eli Lilly's 2026 revenue guidance stands at $87 billion.
- The next confirmable event is a formal filing that will break out product-level revenue detail for Zepbound and Mounjaro.
LLY is in focus after Eli Lilly easily topped quarterly earnings estimates and raised its full-year 2026 revenue outlook, with Zepbound and Mounjaro sales cited as the demand catalyst. The company now guides for 2026 revenue of $85 billion to $87 billion, against a prior range of $82 billion to $85 billion. The next confirmable event is the formal filing that will carry product-level revenue detail.
The guidance raise
Both ends of Eli Lilly's 2026 revenue range moved higher after Zepbound and Mounjaro exceeded sales expectations in the quarter. The low end rose from $82 billion to $85 billion. The high end moved from $85 billion to $87 billion, setting a new ceiling for the year.
Lilly pointed directly to the two drugs as the reason for the raised guidance. With the beat in hand and the full-year range lifted at both bounds, analyst consensus will need to reset to the new band.
The setup for LLY
A guidance raise that moves both the floor and ceiling is a more confident signal than a low-end adjustment alone. Lilly is telling the tape that Zepbound and Mounjaro demand held well enough in the quarter to justify revised expectations for the full year.
The key variable is whether that sales pace sustains through the second half.
What to watch
The formal filing will break out product-level figures. Watch the revenue split between Zepbound and Mounjaro. Concentration in one drug while the other flattens would complicate the read on full-year durability.
The new ceiling for Eli Lilly's 2026 revenue guidance stands at $87 billion.